Anavex Life Sciences Corp (AVXL)

[sokol]

I plan on not raising my expectations to such a high level that I may be disappointed in the news we are about to hear. We should keep in mind that if the clinical trial demonstrates that at 41 weeks the participating patients in this trial have at least maintained a cognitive and activities level above what Alzheimers' patients traditionally or historically experience without AVXL 2-73 that is an encouraging and successful result. Heretofore, nothing has stopped or slowed the progression of this disease, and Alzheimer's patients have continued to decline over such a period of time. Having said that, I am hopeful that a larger phase 3 trial exhibits even better AVXL 2-73 effects. It is becoming clearer to me that mono-therapy is the path going forward. Perhaps also some other lessons have been learned that may be of benefit in the larger trial.